Biomedical subjects

A Mohos

Publications and source records attributed to A Mohos.

4 recordsLinked to original sources

PubMed2000

[Combined chemotherapy after prolonged oral etoposide maintenance therapy in patients with small-cell lung cancer].

The authors have reported the results of induction, and maintenance therapy of 36 patients suffering from small-cell lung cancer. The induction chemotherapy with cisplatin and etoposide proved to be successful in 34 cases out of the 36 patients. The patients were divided in two groups following the induction treatment: with 17 patients no further chemotherapy happened. The other 17 patients received maintenance cytotoxic treatment with prolonged oral etoposide. There was a significant increase in the average survival time in cases of patients who received maintenance therapy (p < 0.001). The average survival of these patients was 908.4 days, while that of the patients of the control group proved to be 404.5 days.

Administration, Oral↗

PubMed1999

[Chylothorax after blunt chest trauma].

An unusually lately discovered and successfully treated case with right sided chylothorax after blunt chest trauma is presented. Pathogenesis of chylothorax, diagnostic and treatment modalities are summarised.

Chylothorax↗

PubMed1997

[Prolonged oral etoposide therapy in advanced stage lung cancer].

Authors discuss results of the prolonged oral etoposide treatment of 79 patients with advanced stage lung cancer. Thirty patients with small-cell lung cancer were treated with Cisplatin in combination with prolonged oral etoposide. Response rate was nearly 100%. Most of the patients (24) were in partial remission, and the mean survival time was 15 months. Forty-nine patients with non-small cell lung cancer were divided at random into two groups: patients in the first group (n = 25) were treated with Cisplatin in combination with prolonged oral etoposide. In the second group (n = 24) was used only prolonged oral etoposide therapy for 14-, or 21 days. Encouraging response rate have been observed with long-term daily administration of oral etoposide to treat non-small cell lung cancer. In both groups there was a response rate nearly 80%. Most of the patients in these two subgroups got into partial remission, and a rest were in stable clinical stage (median duration was 5 months). Besides alopecia, which occurred in all patients, myelosuppression (agranulocytosis) was the predominate toxicity (agranulocytosis in 5 cases), which was affectively treated with combined supportive care. Etoposide given by this dose and schedule (100 mg/d for 14 days) has activity as first-line systemic therapy in combination with Cisplatin for advanced small-cell lung cancer and, has a moderate activity for treatment of non-small cell lung cancer.

Administration, Oral↗

PubMed1997

[Hematologic abnormalities in pulmonary tuberculosiss].

This study surveys the extent and severity of haematological abnormalities which occurred in 380 patients with pulmonary tuberculosis. Full blood count, bone marrow aspiration smears, and bone marrow trephine biopsy was analyzed by authors. Anaemia was present in 32 percent of patients. Leucocytosis with neutrophilia occurred in 18 percent. Leucopenia with neutropenia, and lymphopenia was observed in 16 percent in patients with very severe clinical tuberculosis. Elevated platelet count occurred in 8 percent with deep vein thrombosis in legs in 50 percent. Dysmyelopoietic syndrome was diagnosed in one case by bone marrow trephine biopsy. There was a close correlation between the haematological abnormalities and the severity of clinical findings of pulmonary tuberculosis. This survey has revealed that haematological abnormalities are relatively common in severe pulmonary tuberculosis. It seems that body weight loss, white blood cell count, haemoglobin level and erythrocyte sedimentation rate are useful indices of severity of the tuberculosis. The return of these indices to a normal level is a good indication of disease control in that they correlate with sputum conversion to acid-fast bacilli negative.

Anemia↗